These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
277 related articles for article (PubMed ID: 33270549)
21. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170 [TBL] [Abstract][Full Text] [Related]
22. Characteristics and current clinical practices of opioid treatment programs in the United States. Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836 [TBL] [Abstract][Full Text] [Related]
23. A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment. Rudolf G; Walsh J; Plawman A; Gianutsos P; Alto W; Mancl L; Rudolf V Am J Drug Alcohol Abuse; 2018; 44(3):302-309. PubMed ID: 28795846 [TBL] [Abstract][Full Text] [Related]
24. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices. Andraka-Christou B; Capone MJ Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial. Dunn KE; Tompkins DA; Bigelow GE; Strain EC JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791 [TBL] [Abstract][Full Text] [Related]
26. Hospital-initiated Extended-release Injectable Buprenorphine Using a Novel Reallocation Initiative From an Outpatient Addiction Medicine Clinic. Ganetsky VS; Salzman M; Carroll G; Heil J; Sutton J; Visioli VM; Currie S; Schmidt R; Baston KE; Haroz R J Addict Med; 2023 Jan-Feb 01; 17(1):108-110. PubMed ID: 36166670 [TBL] [Abstract][Full Text] [Related]
27. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review. Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448 [TBL] [Abstract][Full Text] [Related]
28. Pharmacotherapy for Substance Use Disorders. Klein JW Med Clin North Am; 2016 Jul; 100(4):891-910. PubMed ID: 27235620 [TBL] [Abstract][Full Text] [Related]
29. County-level access to opioid use disorder medications in medicare Part D (2010-2015). Abraham AJ; Adams GB; Bradford AC; Bradford WD Health Serv Res; 2019 Apr; 54(2):390-398. PubMed ID: 30665272 [TBL] [Abstract][Full Text] [Related]
30. Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter. Tofighi B; El Shahawy O; Segoshi A; Moreno KP; Badiei B; Sarker A; Krawczyk N J Addict Dis; 2021; 39(1):37-45. PubMed ID: 32835641 [No Abstract] [Full Text] [Related]
31. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results. Klein AA; Seppala MD J Subst Abuse Treat; 2019 Sep; 104():51-63. PubMed ID: 31370985 [TBL] [Abstract][Full Text] [Related]
32. Update on pharmacotherapy for treatment of opioid use disorder. Ayanga D; Shorter D; Kosten TR Expert Opin Pharmacother; 2016 Dec; 17(17):2307-2318. PubMed ID: 27734745 [TBL] [Abstract][Full Text] [Related]
33. Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Korthuis PT; Lum PJ; Vergara-Rodriguez P; Ahamad K; Wood E; Kunkel LE; Oden NL; Lindblad R; Sorensen JL; Arenas V; Ha D; Mandler RN; McCarty D; Addiction; 2017 Jun; 112(6):1036-1044. PubMed ID: 28061017 [TBL] [Abstract][Full Text] [Related]
34. Naltrexone Treatment for Pregnant Women With Opioid Use Disorder Compared With Matched Buprenorphine Control Subjects. Wachman EM; Saia K; Miller M; Valle E; Shrestha H; Carter G; Werler M; Jones H Clin Ther; 2019 Sep; 41(9):1681-1689. PubMed ID: 31358302 [TBL] [Abstract][Full Text] [Related]
35. Diagnosis and Management of Opioid Use Disorder in Hospitalized Patients. Herscher M; Fine M; Navalurkar R; Hirt L; Wang L Med Clin North Am; 2020 Jul; 104(4):695-708. PubMed ID: 32505261 [TBL] [Abstract][Full Text] [Related]
36. Medication-Assisted Treatment for Opioid-Use Disorder. Oesterle TS; Thusius NJ; Rummans TA; Gold MS Mayo Clin Proc; 2019 Oct; 94(10):2072-2086. PubMed ID: 31543255 [TBL] [Abstract][Full Text] [Related]
37. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women. Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191 [TBL] [Abstract][Full Text] [Related]
38. Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review. Mackey K; Veazie S; Anderson J; Bourne D; Peterson K J Gen Intern Med; 2020 Dec; 35(Suppl 3):954-963. PubMed ID: 33145687 [TBL] [Abstract][Full Text] [Related]
39. Effect of Integrating Substance Use Disorder Treatment into Primary Care on Inpatient and Emergency Department Utilization. Wakeman SE; Rigotti NA; Chang Y; Herman GE; Erwin A; Regan S; Metlay JP J Gen Intern Med; 2019 Jun; 34(6):871-877. PubMed ID: 30632103 [TBL] [Abstract][Full Text] [Related]